# US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

> **NCT04103879** · PHASE2 · COMPLETED · sponsor: **ExCellThera inc.** · enrollment: 30 (actual)

## Conditions studied

- High Risk Hematological Malignancy
- Cord Blood Transplant

## Interventions

- **BIOLOGICAL:** ECT-001-CB (UM171-Expanded Cord Blood Transplant)

## Key facts

- **NCT ID:** NCT04103879
- **Lead sponsor:** ExCellThera inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-13
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04103879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04103879, "US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04103879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*